<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620862</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-DED-Ly -K01</org_study_id>
    <nct_id>NCT05620862</nct_id>
  </id_info>
  <brief_title>Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors</brief_title>
  <official_title>Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I dose escalation clinical trial: to explore the dose limiting toxicity (DLT) of&#xD;
      mitoxantrone hydrochloride liposome injection in the treatment of children with relapsed and&#xD;
      refractory lymphoma and solid tumors.&#xD;
&#xD;
      Pharmacokinetics clinical trial: to observe the pharmacokinetics of mitoxantrone&#xD;
      hydrochloride liposomes in children with relapsed and refractory lymphoma and solid tumors.&#xD;
&#xD;
      To evaluate the safety and efficacy of mitoxantrone hydrochloride liposomes in children with&#xD;
      lymphoma and solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I dose escalation and pharmacokinetics clinical trial to evaluate the safety&#xD;
      and efficacy of mitoxantrone hydrochloride liposomes in children with lymphoma and solid&#xD;
      tumors. In the phase I dose escalation study 9-18 children with relapsed and refractory&#xD;
      lymphoma and solid tumors will be treated with mitoxantrone hydrochloride liposome alone at&#xD;
      the dose of 16 mg/m2, 20 mg/m2 and 24 mg/m2. Simultaneously 6~15 cases were added for&#xD;
      pharmacokinetic study to ensure 8 cases are included in each dose group with the same&#xD;
      mitoxantrone hydrochloride liposome dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2022</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum-tolerated dose</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To investigate the safety and preliminary antitumor efficacy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>peak time (Tmax)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>To evaluate the pharmacokinetics of mitoxantrone hydrochloride liposome at different doses in subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>To evaluate the pharmacokinetics of mitoxantrone hydrochloride liposome at different doses in subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>To evaluate the pharmacokinetics of mitoxantrone hydrochloride liposome at different doses in subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half life (t1/2)</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>To evaluate the pharmacokinetics of mitoxantrone hydrochloride liposome at different doses in subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose limiting toxicities</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To investigate the safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>To investigate the preliminary antitumor efficacy of phase I dose escalation and pharmacokinetics study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>To investigate the preliminary antitumor efficacy of phase I dose escalation and pharmacokinetics study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 70 weeks</time_frame>
    <description>To investigate the preliminary antitumor efficacy of phase I dose escalation and pharmacokinetics study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence and severity of AE and SAE</measure>
    <time_frame>up to 42 weeks unless related serious adverse events need to be recorded indefinitely</time_frame>
    <description>To identify the incidence and severity of AE and SAE (NCI CTCAE v5.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Lymphoma, Solid Tumors</condition>
  <arm_group>
    <arm_group_label>mitoxantrone hydrochloride liposome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children with relapsed and refractory lymphoma and solid tumors will receive mitoxantrone hydrochloride liposome alone at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 for up to 6 cycles (21 days per cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone Hydrochloride Liposome</intervention_name>
    <description>Mitoxantrone hydrochloride liposome will be administered by an intravenous infusion at three doses of 16 mg/m2, 20 mg/m2 and 24 mg/m2 for up to 6 cycles (21 days per cycle).</description>
    <arm_group_label>mitoxantrone hydrochloride liposome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Subjects fully understand and voluntarily participate in this study and sign the&#xD;
             informed consent form (ICF);&#xD;
&#xD;
          -  2. 5-18 years old;&#xD;
&#xD;
          -  3. Expected survival ≥ 3 months;&#xD;
&#xD;
          -  4. Subjects with histologically confirmed diagnosis of relapsed and refractory&#xD;
             lymphoma and solid tumors, which is one of the following subtypes:&#xD;
&#xD;
               1. Lymphoblastic lymphoma&#xD;
&#xD;
               2. Anaplastic large T cell lymphoma&#xD;
&#xD;
               3. Burkitt's lymphoma&#xD;
&#xD;
               4. Diffuse large B-cell lymphoma&#xD;
&#xD;
               5. Peripheral T, NK/T cell lymphoma&#xD;
&#xD;
               6. Soft tissue sarcoma&#xD;
&#xD;
               7. Neuroblastoma&#xD;
&#xD;
               8. Other subtypes of lymphoma or solid tumors that the investigators believe can be&#xD;
                  included&#xD;
&#xD;
          -  5. Relapsed lymphoma is defined as the lymphoma that relapse after obtaining complete&#xD;
             response (CR) after initial chemotherapy; Refractory lymphoma subjects meet one of the&#xD;
             following conditions: 1) The tumor shrinks &lt;50% or disease progression after 4 cycles&#xD;
             of standard chemotherapy,; 2) CR after standard chemotherapy, but relapse within half&#xD;
             a year; 3) 2 or more relapses after CR; 4) relapse after hematopoietic stem cell&#xD;
             transplantation;&#xD;
&#xD;
          -  6. Lymphoma subjects must have at least one evaluable or measurable lesion per&#xD;
             lugano2014 criteria: for lymph node lesions, the length should be &gt; 1.5cm; For&#xD;
             non-lymph node lesions, the length should be &gt; 1.0cm;&#xD;
&#xD;
          -  7. Solid tumors must have tumor lesions measurable by CT or MRI;&#xD;
&#xD;
          -  8. ECOG Performance Status: 0-2;&#xD;
&#xD;
          -  9. Bone marrow function: Absolute neutrophil count ≥1.5×109/L, Platelet count&#xD;
             ≥75×109/L, Hemoglobin ≥ 80g/L (Absolute neutrophil can be relaxed to ≥ 1.0×109/L,&#xD;
             Platelet count can be relaxed to ≥50×109/L, Hemoglobin can be relaxed to ≥75 g/L in&#xD;
             subjects with poor bone-marrow reserve);&#xD;
&#xD;
          -  10. Liver and kidney function: serum creatinine ≤ 1.5×ULN (upper limit of normal); AST&#xD;
             and ALT ≤ 2.5×ULN (≤ 5×ULN for subjects with liver metastases); total bilirubin ≤&#xD;
             1.5×ULN (≤ 3×ULN for subjects with liver metastases).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. The subject had previously received any of the following anti-tumor treatments:&#xD;
&#xD;
               1. Subjects who have been treated with mitoxantrone or mitoxantrone liposomes;&#xD;
&#xD;
               2. Previously received doxorubicin or other anthracycline treatment, and the total&#xD;
                  cumulative dose of doxorubicin was more than 360 mg/m2 (1 mg doxorubicin&#xD;
                  equivalent to 2 mg epirubicin);&#xD;
&#xD;
               3. Subjects who received anti-tumor treatment (including chemotherapy, targeted&#xD;
                  therapy, glucocorticoid, traditional Chinese medicine with anti-tumor activity,&#xD;
                  etc.) or participated in other clinical trials and received trial drugs;&#xD;
&#xD;
               4. Subjects who received autologous hematopoietic stem cell transplantation within&#xD;
                  100 days after the first medication or allogeneic hematopoietic stem cell&#xD;
                  transplantation.&#xD;
&#xD;
          -  2. Hypersensitivity to any study drug or its components;&#xD;
&#xD;
          -  3. Uncontrolled systemic diseases (such as active infection, uncontrolled&#xD;
             hypertension, diabetes, etc.);&#xD;
&#xD;
          -  4. Heart function and disease meet one of the following conditions:&#xD;
&#xD;
               1. Long QTc syndrome or QTc interval &gt; 480 ms;&#xD;
&#xD;
               2. Complete left bundle branch block, grade II or III atrioventricular block;&#xD;
&#xD;
               3. Serious and uncontrolled arrhythmias requiring drug treatment;&#xD;
&#xD;
               4. New York Heart Association grade ≥ III;&#xD;
&#xD;
               5. Cardiac ejection fraction (LVEF)&lt; 50%;&#xD;
&#xD;
               6. A history of myocardial infarction, unstable angina pectoris, severe unstable&#xD;
                  ventricular arrhythmia or any other arrhythmia requiring treatment, a history of&#xD;
                  clinically serious pericardial disease, or ECG evidence of acute ischemia or&#xD;
                  active conduction system abnormalities within 6 months before recruitment.&#xD;
&#xD;
          -  5. Hepatitis B and hepatitis C active infection (plus HBV DNA if one positive for&#xD;
             hepatitis B surface antigen or core antibody and HBV DNA more than 1×103 copy/mL&#xD;
             excluded; plus HCV RNA if hepatitis C antibody positive and HCV RNA more than 1×103&#xD;
             copy/mL exclude);&#xD;
&#xD;
          -  6. Human immunodeficiency virus (HIV) infection (HIV antibody positive);&#xD;
&#xD;
          -  7. Subjects with other malignant tumors past or present (except for non-melanoma skin&#xD;
             basal cell carcinoma, breast/cervical carcinoma in control, and other malignant tumors&#xD;
             that have been effectively controlled without treatment within the past five years);&#xD;
&#xD;
          -  8. Subjects suffering from primary or secondary central nervous system (CNS) lymphoma&#xD;
             or a history of CNS lymphoma at the time of recruitment;&#xD;
&#xD;
          -  9. Pregnant and lactating women and childbearing age patients unwilling to take&#xD;
             contraceptive measures;&#xD;
&#xD;
          -  10. Unsuitable subjects for this study determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yizhuo Zhang, PhD</last_name>
    <phone>020-87342460</phone>
    <email>zhangyzh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Zhuo Zhang, MD</last_name>
      <phone>18622221239</phone>
      <email>zhangyzh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Yi-Zhuo Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yizhuo Zhang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

